Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Kevin T. Palka

Hematology Oncology | Hematology | Oncology
Hannibal Regional Hospital
Hannibal Regional Healthcare System Inc
6500 Hospital Dr, 
Hannibal, MO 
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Hannibal Regional Hospital
Hannibal Regional Healthcare System Inc
6500 Hospital Dr, 
Hannibal, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kevin Palka is a Hematologist Oncology specialist and a Hematologist in Hannibal, Missouri. Dr. Palka is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Prostate Cancer, Prostate Cancer, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Hannibal Regional Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

HANNIBAL REGIONAL HEALTHCARE SYSTEM INC
6500 Hospital Dr, Hannibal, MO 63401
Call: 573-248-1300

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


17 Clinical Trials

Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drugs: APL-101, Osimertinib
Study Phase: Phase 1/Phase 2
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial
Enrollment Status: Recruiting
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Cetuximab
Study Phase: Phase 3
Non-Randomized Phase 2 Trial of Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
Non-Randomized Phase 2 Trial of Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drug: CUE-101
Study Phase: Phase 2
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Vorolanib, Atezolizumab
Study Phase: Phase 2
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drug: Cisplatin
Study Phase: Phase 2
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drugs: Mitomycin C, Pegfilgrastim
Study Phase: Phase 2
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Palbociclib, Cetuximab, Cisplatin
Study Phase: Phase 2
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Drug, Procedure
Study Drugs: Olaparib, Pembrolizumab, Carboplatin
Study Phase: Phase 2
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 2
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 Trial
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Nab-paclitaxel, Nivolumab
Study Phase: Phase 2
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug, Radiation, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Cetuximab
Study Phase: Phase 2
A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Ramucirumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Enrollment Status: Terminated
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drugs: Mycophenolate Mofetil, Allopurinol, Irinotecan
Study Phase: Phase 1
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial
Enrollment Status: Terminated
Publish Date: February 21, 2024
Intervention Type: Drug
Study Drugs: Tazemetostat, Pembrolizumab
Study Phase: Phase 1
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug, Biological
Study Drugs: Cetuximab, PD 0332991
Study Phase: Phase 1/Phase 2
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Enrollment Status: Terminated
Publish Date: December 03, 2020
Intervention Type: Procedure, Drug, Other
Study Phase: Phase 1/Phase 2
View 14 Less Clinical Trials

6 Total Publications

nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.
nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.
Journal: Medical oncology (Northwood, London, England)
Published: November 10, 2020
View All 6 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mohammed I. Memon
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mohammed I. Memon
Hematology Oncology | Hematology | Oncology

Blessing Hospital

1005 Broadway St, 
Quincy, IL 
 (15.9 miles away)
217-223-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammed Memon is a Hematologist Oncology specialist and a Hematologist in Quincy, Illinois. Dr. Memon is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Memon is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Arif A. Bari
Hematology Oncology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Arif A. Bari
Hematology Oncology | Oncology

Blessing Hospital

5985 Hospital Dr, 
Hannibal, MO 
 (0.1 miles away)
573-406-5800
Languages Spoken:
English
See accepted insurances

Arif Bari is a Hematologist Oncology specialist and an Oncologist in Hannibal, Missouri. Dr. Bari is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Angiosarcoma, and Inflammatory Breast Cancer.

Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Muhammad A. Ali
Hematology Oncology | Oncology | Hematology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Muhammad A. Ali
Hematology Oncology | Oncology | Hematology

Blessing Hospital

5985 Hospital Dr, 
Hannibal, MO 
 (0.1 miles away)
573-406-5800
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients

Muhammad Ali is a Hematologist Oncology specialist and an Oncologist in Hannibal, Missouri. Dr. Ali is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Chronic Familial Neutropenia, Paget Disease of the Breast, and Colonoscopy. Dr. Ali is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Palka's expertise for a condition
ConditionClose
      • Advanced
      • ALK-Positive Non-Small Cell Lung Cancer
        Dr. Palka is
        Advanced
        . Learn about ALK-Positive Non-Small Cell Lung Cancer.
        See more ALK-Positive Non-Small Cell Lung Cancer experts
      • Breast Cancer
        Dr. Palka is
        Advanced
        . Learn about Breast Cancer.
        See more Breast Cancer experts
      • EGFR Positive Lung Cancer
        Dr. Palka is
        Advanced
        . Learn about EGFR Positive Lung Cancer.
        See more EGFR Positive Lung Cancer experts
      • Familial Prostate Cancer
        Dr. Palka is
        Advanced
        . Learn about Familial Prostate Cancer.
        See more Familial Prostate Cancer experts
      • Head and Neck Squamous Cell Carcinoma (HNSCC)
        Dr. Palka is
        Advanced
        . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
        See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
      • Large-Cell Lung Carcinoma
        Dr. Palka is
        Advanced
        . Learn about Large-Cell Lung Carcinoma.
        See more Large-Cell Lung Carcinoma experts
      View All 14 Advanced Conditions
      • Experienced
      • Acute Mountain Sickness
        Dr. Palka is
        Experienced
        . Learn about Acute Mountain Sickness.
        See more Acute Mountain Sickness experts
      • Adult Immune Thrombocytopenia
        Dr. Palka is
        Experienced
        . Learn about Adult Immune Thrombocytopenia.
        See more Adult Immune Thrombocytopenia experts
      • Adult Soft Tissue Sarcoma
        Dr. Palka is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • Agranulocytosis
        Dr. Palka is
        Experienced
        . Learn about Agranulocytosis.
        See more Agranulocytosis experts
      • Anaplastic Large Cell Lymphoma
        Dr. Palka is
        Experienced
        . Learn about Anaplastic Large Cell Lymphoma.
        See more Anaplastic Large Cell Lymphoma experts
      • Anemia
        Dr. Palka is
        Experienced
        . Learn about Anemia.
        See more Anemia experts
      View All 86 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2025 All Rights Reserved